Loading...
India's glimepiride imports from UNITED KINGDOM total $78 across 1 shipments from 1 foreign suppliers. E- PHARM LIMITED leads with $78 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MACLEODS PHARMACEUTICALS LTD. This corridor reflects India's pharmaceutical import demand for glimepiride — a concentrated sourcing relationship with select suppliers from UNITED KINGDOM.
E- PHARM LIMITED is the leading Glimepiride supplier from UNITED KINGDOM to India, with import value of $78 across 1 shipments. The top 5 suppliers — E- PHARM LIMITED — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | E- PHARM LIMITED | $78 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MACLEODS PHARMACEUTICALS LTD | $78 | 1 | 100.0% |
UNITED KINGDOM → India trade corridor intelligence
As of April 2026, the United Kingdom to India trade corridor for pharmaceutical imports, including Glimepiride formulations, is operating efficiently. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are handling shipments without significant congestion. Freight rates have stabilized, and the exchange rate between the Indian Rupee (INR) and the British Pound remains favorable for importers. The logistics infrastructure supports timely deliveries, ensuring a steady supply of Glimepiride formulations from the United Kingdom to India.
The Production Linked Incentive (PLI) scheme introduced by the Indian government aims to boost domestic manufacturing and reduce import dependency. While this policy encourages local production, it has led to a decrease in the import of certain pharmaceutical products, including some Glimepiride formulations. However, specialized formulations not produced domestically continue to be imported from the United Kingdom to meet market demand. The policy reflects India's commitment to self-reliance while recognizing the need for certain imports to fulfill specific therapeutic requirements.
The trade relationship between India and the United Kingdom is robust, with ongoing negotiations to enhance bilateral ties, including in the pharmaceutical sector. Discussions focus on mutual recognition of Good Manufacturing Practices (GMP), facilitating smoother trade and regulatory processes. Efforts are also underway to streamline approval procedures for pharmaceutical imports, aiming to reduce lead times and costs. These initiatives are expected to strengthen the pharmaceutical trade corridor between the two nations.
The landed cost of importing Glimepiride formulations from the United Kingdom to India includes several components:
The total landed cost per unit depends on these factors and can vary based on the specific terms of the transaction and prevailing rates.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Glimepiride into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the foreign manufacturer and the Indian importer obtain necessary approvals. The foreign manufacturer must possess a valid Certificate of Pharmaceutical Product (CoPP) issued by the regulatory authority of the United Kingdom. The Indian importer is required to obtain an Import License from the Directorate General of Foreign Trade (DGFT) and ensure that the product is registered with CDSCO. The registration process involves submitting Form 40/41, along with supporting documents such as the CoA, CoPP, and stability data. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process. For Glimepiride formulations under HS Code 30049099, compliance with the Indian Pharmacopoeia standards is mandatory. Additionally, the product must meet the labeling requirements specified by CDSCO, including details like the trade name, generic name, net content, batch number, and manufacturing date.
Imported Glimepiride formulations are subject to quality testing by CDSCO-approved laboratories in India. Each batch must undergo testing to verify its compliance with the Indian Pharmacopoeia standards. The Certificate of Analysis (CoA) provided by the foreign manufacturer should include detailed information on the product's composition, manufacturing process, and stability data. Stability studies must be conducted under conditions specified by the International Council for Harmonisation (ICH) Zone IV guidelines, considering India's climatic conditions. Upon arrival at Indian ports, customs drug inspectors perform inspections to ensure that the imported batches conform to the approved specifications. If a batch fails to meet the required standards, it may be rejected, and the importer could face penalties or be barred from future imports.
Between 2024 and 2026, CDSCO has implemented stricter regulations for the importation of pharmaceutical products, including finished formulations containing Glimepiride. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, leading to a reduction in the import of certain pharmaceutical products. Additionally, bilateral agreements between India and the United Kingdom have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined approval processes for imported pharmaceutical products. These developments aim to enhance the quality and availability of pharmaceutical products in the Indian market while promoting self-reliance.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Glimepiride formulations primarily due to the demand for patented or branded products that are not manufactured domestically. Specific dosage forms, such as extended-release tablets or combination therapies, may not be produced locally, necessitating imports. While India has a robust pharmaceutical manufacturing sector, certain specialized formulations require external sourcing to meet patient needs. The market size for Glimepiride formulations in India is substantial, with a growing prevalence of diabetes driving demand. However, the exact market size and import dependency ratio are subject to market dynamics and regulatory changes.
The import of Glimepiride formulations under HS Code 30049099 into India is subject to a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is levied as per the prevailing rates, which are subject to change. There are no specific exemptions or concessional duties for imports from the United Kingdom under this HS code. The total landed duty percentage varies based on the IGST rate and other applicable charges, impacting the final cost of imported formulations.
India sources Glimepiride formulations from the United Kingdom due to the availability of patented formulations and specialized dosage forms that are not produced domestically. The United Kingdom's pharmaceutical industry is known for its high-quality standards and adherence to international regulatory requirements, providing a competitive advantage in the Indian market. While other suppliers, such as China, Germany, and the United States, also export pharmaceutical products to India, the United Kingdom's reputation for quality and innovation makes it a preferred source for certain formulations. The United Kingdom's share in India's Glimepiride import market is significant, reflecting its strong position as a supplier.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Glimepiride formulations from the United Kingdom due to the availability of patented formulations and specialized dosage forms that are not manufactured domestically. The United Kingdom's pharmaceutical industry is known for its high-quality standards and adherence to international regulatory requirements, providing a competitive advantage in the Indian market. These factors make the United Kingdom a preferred source for certain Glimepiride formulations.
When compared to other suppliers such as China, Germany, and the United States, the United Kingdom offers advantages in terms of quality, regulatory compliance, and reliability. The United Kingdom's pharmaceutical products are recognized for their adherence to stringent quality standards and international regulations, making them a preferred choice for Indian importers seeking high-quality Glimepiride formulations.
Indian importers face several supply chain risks when sourcing Glimepiride formulations from the United Kingdom, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with multiple suppliers. Additionally, staying informed about regulatory changes and market dynamics is crucial for effective risk management.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Glimepiride suppliers from UNITED KINGDOM to India include E- PHARM LIMITED. The leading supplier is E- PHARM LIMITED with import value of $78 USD across 1 shipments. India imported Glimepiride worth $78 USD from UNITED KINGDOM in total across 1 shipments.
India imported Glimepiride worth $78 USD from UNITED KINGDOM across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Glimepiride sourced from UNITED KINGDOM include MACLEODS PHARMACEUTICALS LTD. The largest buyer is MACLEODS PHARMACEUTICALS LTD with $78 in imports across 1 shipments.
The total value of Glimepiride imports from UNITED KINGDOM to India is $78 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists